Crinetics Pharmaceuticals, Inc.
CRNX
$37.48
$0.571.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 18.07M | 7.70M | 1.54M | 1.39M | 760.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.07M | 7.70M | 1.54M | 1.39M | 760.00K |
| Cost of Revenue | 357.18M | 333.13M | 313.57M | 285.01M | 263.06M |
| Gross Profit | -339.11M | -325.44M | -312.04M | -283.62M | -262.30M |
| SG&A Expenses | 206.64M | 191.33M | 165.81M | 139.44M | 114.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 563.81M | 524.47M | 479.38M | 424.45M | 377.49M |
| Operating Income | -545.74M | -516.77M | -477.85M | -423.06M | -376.73M |
| Income Before Tax | -496.21M | -465.14M | -423.10M | -369.83M | -328.25M |
| Income Tax Expenses | 180.00K | 180.00K | -- | -- | -- |
| Earnings from Continuing Operations | -496.39 | -465.32 | -423.10 | -369.83 | -328.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -496.39M | -465.32M | -423.10M | -369.83M | -328.25M |
| EBIT | -545.74M | -516.77M | -477.85M | -423.06M | -376.73M |
| EBITDA | -541.62M | -512.88M | -474.16M | -419.62M | -373.49M |
| EPS Basic | -5.13 | -4.94 | -4.53 | -4.11 | -3.82 |
| Normalized Basic EPS | -3.21 | -3.09 | -2.83 | -2.57 | -2.39 |
| EPS Diluted | -5.13 | -4.94 | -4.53 | -4.11 | -3.82 |
| Normalized Diluted EPS | -3.21 | -3.09 | -2.83 | -2.57 | -2.39 |
| Average Basic Shares Outstanding | 387.20M | 376.20M | 372.60M | 358.48M | 343.70M |
| Average Diluted Shares Outstanding | 387.20M | 376.20M | 372.60M | 358.48M | 343.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |